Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P.

Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare ... release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43 rd Annual J.P. Morgan Healthcare Conference ...

Zemansky covers the Healthcare sector, focusing on stocks such as Insmed, Arcus Biosciences, and Cytokinetics. Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average ...

CK-4015089 is under clinical development by Cytokinetics and currently in Phase I for Muscular Dystrophy. According to GlobalData, Phase I drugs for Muscular Dystrophy does not have sufficient ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of ...

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

In the health and medicine field, 2024 will be remembered for advancements in the prevention of HIV, a notable drop in the rate of obesity in the U.S., the murder of an insurance company CEO that ...